Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

95 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunotherapy with ponezumab for probable cerebral amyloid angiopathy.
Leurent C, Goodman JA, Zhang Y, He P, Polimeni JR, Gurol ME, Lindsay M, Frattura L, Sohur US, Viswanathan A, Bednar MM, Smith EE; Ponezumab Trial Study Group; Greenberg SM. Leurent C, et al. Among authors: bednar mm. Ann Clin Transl Neurol. 2019 Mar 18;6(4):795-806. doi: 10.1002/acn3.761. eCollection 2019 Apr. Ann Clin Transl Neurol. 2019. PMID: 31020004 Free PMC article.
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup.
Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, Scheltens P, Carrillo MC, Thies W, Bednar MM, Black RS, Brashear HR, Grundman M, Siemers ER, Feldman HH, Schindler RJ. Sperling RA, et al. Among authors: bednar mm. Alzheimers Dement. 2011 Jul;7(4):367-85. doi: 10.1016/j.jalz.2011.05.2351. Alzheimers Dement. 2011. PMID: 21784348 Free PMC article. Review.
Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.
Landen JW, Zhao Q, Cohen S, Borrie M, Woodward M, Billing CB Jr, Bales K, Alvey C, McCush F, Yang J, Kupiec JW, Bednar MM. Landen JW, et al. Among authors: bednar mm. Clin Neuropharmacol. 2013 Jan-Feb;36(1):14-23. doi: 10.1097/WNF.0b013e31827db49b. Clin Neuropharmacol. 2013. PMID: 23334070 Clinical Trial.
Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy.
Landen JW, Cohen S, Billing CB Jr, Cronenberger C, Styren S, Burstein AH, Sattler C, Lee JH, Jack CR Jr, Kantarci K, Schwartz PF, Duggan WT, Zhao Q, Sprenger K, Bednar MM, Binneman B. Landen JW, et al. Among authors: bednar mm. Alzheimers Dement (N Y). 2017 May 10;3(3):339-347. doi: 10.1016/j.trci.2017.04.003. eCollection 2017 Sep. Alzheimers Dement (N Y). 2017. PMID: 29067341 Free PMC article.
Ponezumab in mild-to-moderate Alzheimer's disease: Randomized phase II PET-PIB study.
Landen JW, Andreasen N, Cronenberger CL, Schwartz PF, Börjesson-Hanson A, Östlund H, Sattler CA, Binneman B, Bednar MM. Landen JW, et al. Among authors: bednar mm. Alzheimers Dement (N Y). 2017 Jun 8;3(3):393-401. doi: 10.1016/j.trci.2017.05.003. eCollection 2017 Sep. Alzheimers Dement (N Y). 2017. PMID: 29067345 Free PMC article.
95 results